Posted in | News | Medical Sensor

Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method

The Rapid Pathogen Screening, Inc. has been granted the approval of Health Canada for its RPS InflammaDry Detector. It is a ten minute, in office test that lets clinicians detect elevated levels of MMP-9 in tear fluid in patients who have Dry Eye disease. Now that RPS has the medical device license it will market the RPS InflammaDry Detector in Canada, following its recent release in Europe and Asia.

Dr. Robert Sambursky, president and chief medical officer of RPS said that receiving a Medical Device License from Health Canada for the RPS InflammaDry Detector is yet another exciting recent accomplishment for RPS.

Dry Eye was difficult to diagnose as the clinical signs of the disease are not always directly related to patient complaints. Also it was found that inflammation was often present in Dry Eye patients long before the appearance of clinical signs.

Matrix metalloproteinase-9 (MMP-9) is an inflammatory marker that has constantly been shown to be elevated in the tears of patients with Dry Eye disease. Elevated levels of MMP-9 may be a more sensitive marker than clinical signs when diagnosing Dry Eye. The RPS InflammaDry Detector needs a small sample of human tears to detect elevated levels of MMP-9.

Providing clinicians with a rapid and accurate in-office screening test to detect hidden Dry Eye disease will help identify patients that may benefit from preoperative therapy to improve their ocular surface, leading to better surgical and medical patient outcomes said Dr. Robert Sambursky.

Source: Rapid Pathogen Screening, Inc

Joel Scanlon

Written by

Joel Scanlon

Joel emigrated to Australia in 1995 and worked for five years in the mining industry as an exploration geotechnician, using GIS mapping and CAD software. Upon moving to the North Coast of NSW, Australia Joel worked as a graphic designer for a leading consultancy firm. After that, he ran a successful business providing web services to businesses along the eastern seaboard of Australia. During this time, he developed and launched News-Medical.Net. Joel has been working with AZoNetwork since the company was founded in 2000.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 24). Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method. AZoSensors. Retrieved on October 01, 2022 from https://www.azosensors.com/news.aspx?newsID=3186.

  • MLA

    Scanlon, Joel. "Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method". AZoSensors. 01 October 2022. <https://www.azosensors.com/news.aspx?newsID=3186>.

  • Chicago

    Scanlon, Joel. "Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method". AZoSensors. https://www.azosensors.com/news.aspx?newsID=3186. (accessed October 01, 2022).

  • Harvard

    Scanlon, Joel. 2019. Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method. AZoSensors, viewed 01 October 2022, https://www.azosensors.com/news.aspx?newsID=3186.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit